Search results for "Carcinogen"

showing 10 items of 6867 documents

Amyloidosis in Inflammatory Bowel Disease: A Systematic Review of Epidemiology, Clinical Features, and Treatment.

2015

Background and Aims: Amyloidosis is a rare complication of inflammatory bowel disease [IBD]; its low prevalence has hindered both descriptive and therapeutic studies. The aim of this study was to estimate the prevalence of amyloidosis in IBD and the risk factors associated with this complication. Methods: This paper presents an observational study, followed by a systematic review of the epidemiological and clinical characteristics of the disease and a review of the diagnostic and therapeutic options. Results: The prevalence of amyloidosis among IBD patients is 0.53% (95% confidence interval [CI]: 0.32–0.75), although epidemiological data suggest that it may be under-diagnosed. The phenotype…

medicine.medical_specialtymedicine.medical_treatmentDiseaseInflammatory bowel disease03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineEpidemiologymedicinePrevalenceHumansProteinuriabusiness.industryAmyloidosisGastroenterologyImmunosuppressionGeneral MedicineAmyloidosismedicine.diseaseInflammatory Bowel DiseasesSurgeryPhenotypeTreatment Outcome030220 oncology & carcinogenesis030211 gastroenterology & hepatologyObservational studymedicine.symptomComplicationbusinessJournal of Crohn'scolitis
researchProduct

Role of carnoy’s solution in the treatment of keratocystic odontogenic tumor: A systematic review

2016

Introduction and Objective The keratocystic odontogenic tumor is a benign but aggressive neoplasm. As enucleation alone obtains high recurrence rates, some adjuvant treatments such as Carnoy’s solution have been proposed. The aim of this study is to evaluate the reduction of recurrences with the use of Carnoy’s solution as adjuvant in the treatment of keratocystic odontogenic tumors. Material and Methods An electronic search in Pubmed (MEDLINE), ScienceDirect and Cochrane databases was conducted with the key words “odontogenic keratocyst”, “keratocystic odontogenic tumor”, “carnoy’s solution”, “treatment” and “enucleation”. The inclusion criteria were clinical studies using Carnoy’s solutio…

medicine.medical_specialtymedicine.medical_treatmentEnucleationOdontogenic TumorsReviewCarnoy's solution03 medical and health sciences0302 clinical medicinemedicineAdjuvant therapyHumansKeratocystGeneral DentistryAcetic AcidEthanolbusiness.industry030206 dentistry:CIENCIAS MÉDICAS [UNESCO]DermatologyOdontogenicstomatognathic diseasesOtorhinolaryngology030220 oncology & carcinogenesisMeta-analysisUNESCO::CIENCIAS MÉDICASSurgeryKeratocystic Odontogenic TumorChloroformmedicine.symptomOral SurgeryNeoplasm Recurrence LocalbusinessAdjuvantMedicina Oral, Patología Oral y Cirugía Bucal
researchProduct

The central odontogenic fibroma: How difficult can be making a preliminary diagnosis

2016

Central odontogenic fibroma (COF) is a rare benign odontogenic tumor derived from the dental ectomesenchymal tissues. A 16-year-old Caucasian female patient was referred by her dentist for a radiolucent asymptomatic area associated with the crown of the impacted lower right third molar. A preliminary diagnosis of a follicular cyst was supposed. The lesion was surgically removed under general anesthesia together with the impacted tooth. The microscopic diagnosis of the excised tissue revealed an odontogenic fibroma. No clinical or radiographic signs of recurrence were found five years after surgical excision. Despite the various differential diagnoses of homogeneous unilocular and well delim…

medicine.medical_specialtymedicine.medical_treatmentEnucleationOdontologíaCase ReportAsymptomaticOdontogenic FibromaLesionSettore MED/28 - MALATTIE ODONTOSTOMATOLOGICHE03 medical and health sciences0302 clinical medicinestomatognathic systemdifferential diagnosismedicineCentral odontogenic fibromaodontogenic fibromaGeneral Dentistrydentistry (all)Follicular Cystbusiness.industryImpacted toothradiographic imaging030206 dentistrymedicine.disease:CIENCIAS MÉDICAS [UNESCO]microscopic diagnosisCiencias de la saludCurettageimpacted third molarSurgerystomatognathic diseases030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASdifferential diagnosis; impacted third molar; microscopic diagnosis; odontogenic fibroma; radiographic imaging; dentistry (all)medicine.symptomOral SurgerybusinessJournal of Clinical and Experimental Dentistry
researchProduct

Radial free forearm flap versus pectoralis major pedicled flap for reconstruction in patients with tongue cancer : assessment of quality of life

2016

Background This study investigated the quality of life of Chinese patients with tongue cancer who had undergone immediate flap reconstruction surgery. In addition, we compared 2 groups of patients: those who had received radial forearm free flap (RFFF) surgery and others who had received pectoralis major myocutaneous flap (PMMF) surgery. Material and Methods Patients who received RFFF or PMMF reconstruction after primary tongue cancer treated with total and subtotal tongue resection were eligible for the current study. The patients’ demographic data, medical history, and quality of life scores (14-item Oral Health Impact Profile (OHIP-14) and the University of Washington Quality of Life (UW…

medicine.medical_specialtymedicine.medical_treatmentFree Tissue Flaps03 medical and health sciences0302 clinical medicineForearmQuality of lifeTonguemedicineHumansMedical historyTongue NeoplasmGeneral DentistryRadial nervebusiness.industryGlossectomyResearch030206 dentistryPedicled FlapPlastic Surgery Procedures:CIENCIAS MÉDICAS [UNESCO]SurgeryTongue NeoplasmsForearmmedicine.anatomical_structureOtorhinolaryngology030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASGlossectomyQuality of LifeSurgeryOral Surgerybusiness
researchProduct

RANDOMIZED PHASE II STUDY OF FIRST-LINE EVEROLIMUS (EVE) + BEVACIZUMAB (BEV) VERSUS INTERFERON ALFA-2A (IFN) + BEV IN PATIENTS (PTS) WITH METASTATIC …

2012

ABSTRACT Background Study results demonstrated that IFN augments BEV activity and improves median PFS in pts with mRCC. Thus, combination BEV + IFN is a standard first-line treatment option for mRCC. Combining BEV with the mTOR inhibitor EVE may be an efficacious and well-tolerated treatment option. The open-label, phase II RECORD-2 trial compared first-line EVE + BEV and IFN + BEV in mRCC. Patients and methods: Therapy-naive pts with clear cell mRCC and prior nephrectomy were randomized 1:1 to BEV 10 mg/kg IV every 2 weeks with either EVE 10 mg oral daily or IFN (9 MIU SC 3 times/week, if tolerated). Tumour assessments were every 12 weeks. Primary objective was treatment effect on progress…

medicine.medical_specialtymedicine.medical_treatmentGastroenterology03 medical and health sciences0302 clinical medicineProstateInternal medicinemedicineStomatitisObjective response030304 developmental biology0303 health sciencesProteinuriaGenitourinary systembusiness.industryTreatment optionsHematologymedicine.diseaseNephrectomy3. Good healthmedicine.anatomical_structureOncologyTolerability030220 oncology & carcinogenesismedicine.symptombusinessAnnals of Oncology
researchProduct

Prognostic Factors of Death in 151 Adults With Hemophagocytic Syndrome: Etiopathogenically Driven Analysis.

2018

Objective: To characterize the etiologies and clinical features at diagnosis of patients with hemophagocytic lymphohistiocytosis (HLH) and correlate these baseline features with survival using an etiopathogenically guided multivariable model. Patients and Methods: The Spanish Group of Autoimmune Diseases HLH Study Group, formed in 2013, is aimed at collecting adult patients with HLH diagnosed in internal medicine departments between January 3, 2013, and October 28, 2017. Results: The cohort consisted of 151 patients (91 men; mean age, 51.4 years). After a mean follow-up of 17 months (range, 1-142 months), 80 patients died. Time-to-event analyses for death identified a worse survival curve f…

medicine.medical_specialtymedicine.medical_treatmentHLH hemophagocytic lymphohistiocytosislaw.invention03 medical and health sciences0302 clinical medicinelawInternal medicineGC glucocorticoidEpidemiologymedicine030212 general & internal medicineSurvival analysislcsh:R5-920Hemophagocytic lymphohistiocytosisID immunosuppressive drugbusiness.industryMortality ratemedicine.diseaseICU intensive care unitIntensive care unitIVIG intravenous immunoglobulinImmunosuppressive drug030220 oncology & carcinogenesisCohortEtiologylcsh:Medicine (General)businessNK natural killerMayo Clinic proceedings. Innovations, qualityoutcomes
researchProduct

Increased risk of angiosarcoma secondary to cancer radiotherapy: Case series and review of the treatment options.

2020

Angiosarcomas (ASs) are aggressive tumors of vascular endothelial origin, occurring sporadically or in association with prior radiotherapy or chronic lymphedema. With only 1-5% of all sarcomas, the incidence seems low, but for the affected patient due to the extremely poor prognosis and the limited treatment options, the fate is often inevitable. Radiotherapy, chemotherapy, or "target therapy" have been used in the management of AS, but represent individual case decisions without lasting evidence. Over the past few years, breast-conserving surgery followed by radiation therapy, known as breast-conserving therapy (BCT), is being employed as a standard treatment for early-stage breast cancer,…

medicine.medical_specialtymedicine.medical_treatmentHemangiosarcomaBreast NeoplasmsDermatologyMastectomy Segmental030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineBreast cancermedicineHumansAngiosarcomaChemotherapybusiness.industryStandard treatmentIncidence (epidemiology)IncidenceTreatment optionsGeneral Medicinemedicine.diseasePrognosisRadiation therapy030220 oncology & carcinogenesisCancer RadiotherapyRadiologybusinessDermatologic therapyREFERENCES
researchProduct

Hepatitis C virus infection in hemodialyzed patients.

2007

In spite of our present improved knowledge of the epidemiology and pathways of contamination of the hepatitis C virus (HCV), infection still remains a public health problem. One category of patients who have suffered greatly from the consequences of HCV infection is certainly that of hemodialysis patients. In the past, in fact, their need for transfusions exposed these patients to infection and, as a result, subjects on dialysis for over 15 years are today paying the price for those inevitable transfusions, as the virus and its pathways of contagion were unknown then. However, still today, albeit at a much lower prevalence, even subjects with a shorter dialysis age present a higher prevalen…

medicine.medical_specialtymedicine.medical_treatmentHepatitis C virusPopulationBiomedical EngineeringMedicine (miscellaneous)Bioengineering030204 cardiovascular system & hematologymedicine.disease_causeAsymptomaticAntiviral AgentsBiomaterials03 medical and health scienceschemistry.chemical_compoundLiver disease0302 clinical medicineRenal DialysisRisk FactorsInternal medicinemedicineHumanseducationDialysiseducation.field_of_studybusiness.industryRibavirinMortality rateTransfusion ReactionGeneral Medicinemedicine.diseaseHepatitis Cchemistry030220 oncology & carcinogenesisImmunologyHemodialysismedicine.symptombusinessThe International journal of artificial organs
researchProduct

Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of a Multicenter Study from the G…

2018

Abstract Introduction Thrombocytopenia is a common complication after allogeneic hematopoietic stem cell transplantation (allo-SCT). Underlying mechanisms are poorly known and usually multifactorial. Its treatment is not well defined, mostly based in platelet transfusion. Thus, is important to identify new strategies to manage this important post-SCT complication. Romiplostim and Eltrombopag are currently available thrombopoietin receptor agonists (TPO-RAs) that stimulate platelet production. Some studies with very small number of cases have reported their potential efficacy in the allo-SCT setting. For this reason, the aim of our study is to analyze the efficacy and safety of TPO-RAs for s…

medicine.medical_specialtymedicine.medical_treatmentImmunologyEltrombopagHematopoietic stem cell transplantationNeutropeniaBiochemistryGastroenterology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicinemedicinePlateletRomiplostimbusiness.industryCell BiologyHematologymedicine.diseaseTransplantationPlatelet transfusionGraft-versus-host diseasechemistry030220 oncology & carcinogenesisbusiness030215 immunologymedicine.drugBlood
researchProduct

Albumin versus solvent/detergent-treated pooled plasma as replacement fluid for long-term plasma exchange therapy in a patient with primary hypertrig…

2015

BACKGROUND Chylomicronemia syndrome is a metabolic condition characterized by severe fasting hypertrigliceridemia (≥1000 mg/dL) and other clinical features including chronic abdominal pain and recurrent acute pancreatitis. In patients with acute or recurrent pancreatitis, plasma exchange (PEx) is indicated for the treatment of acute disease and prevention of recurrence. The use of plasma instead of albumin as replacement fluid has been suggested for its putative ability to replace the deficient enzyme possibly leading to better clinical improvement. CASE REPORT A 40-year-old man with chylomicronemia syndrome due to a newly identified loss-of-function mutation in the lipoprotein lipase (LPL)…

medicine.medical_specialtymedicine.medical_treatmentImmunologySerum albumin030204 cardiovascular system & hematologyGastroenterology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRecurrent pancreatitisInternal medicinemedicineImmunology and AllergyLipoprotein lipaseTriglyceridebiologybusiness.industryAlbuminHematologymedicine.diseaseEndocrinologychemistry030220 oncology & carcinogenesisbiology.proteinPancreatitisAcute pancreatitisPlasmapheresisbusinessTransfusion
researchProduct